Iván Cornella‐Taracido

Statistics

Publications

Citations

H-Index

Active since

2002

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Novartis (Switzerland)

Novartis (United States)

Harvard University

Boston College

Iván Cornella‐Taracido is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, natural sciences, and pharmacology.

ORCID

Top concepts

MedicineNatural SciencesPharmacologyBiochemistryDrug DiscoveryCell BiologySystems BiologyMolecular BiologyBiomolecular EngineeringCell Signaling

Publications per year

2002–2022

Publications

Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo

William E. Dowdle, Beat Nyfeler, Jane Nagel et al. · Nature Cell Biology · 2014 · 715 citations

Inflammation, Cell Autophagy, Signal Transduction +13

Natural products reveal cancer cell dependence on oxysterol-binding proteins

Anthony W. G. Burgett, Thomas B. Poulsen, Kittikhun Wangkanont et al. · Nature Chemical Biology · 2011 · 255 citations · Full text

Biochemistry, Oncogenic Agent, Medicine +5

Class III Phosphatidylinositol 4-Kinase Alpha and Beta Are Novel Host Factor Regulators of Hepatitis C Virus Replication

Jason Borawski, Philip J.F. Troke, Xiaoling Puyang et al. · Journal of Virology · 2009 · 195 citations · Full text

Viral Replication, Hepatic Disorders, Molecular Virology +15

Progress toward a Rationally Designed, Chemically Powered Rotary Molecular Motor

T. Ross Kelly, Xiaolu Cai, Fehmi Damkaci et al. · Journal of the American Chemical Society · 2006 · 172 citations

Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers

Malvika Koundinya, Judith Sudhalter, Albane Courjaud et al. · Cell chemical biology · 2018 · 118 citations

Biosynthesis, Biochemistry, Natural Sciences +5

1–5 of 21